Group 1 - hince, a niche Korean cosmetics brand, has made significant adjustments to its online presence in China, clearing products from multiple online stores, including its Tmall International flagship store and Douyin overseas flagship store, effective January 1 [1] - The brand previously announced a "suspension of operations" due to strategic adjustments, stating that stores would cease operations on January 1, 2026, but will fulfill existing orders and allow returns within the platform's time limits [1] - A revised announcement on January 9 indicated that the store would undergo a phased adjustment for operational upgrades and service optimization, with ongoing customer service and support [3] Group 2 - hince was established in late 2018 and is owned by Vivawave, emphasizing natural beauty concepts and quickly gaining popularity among the MZ generation in Korea, with sales reaching 21.8 billion KRW in 2022, half of which came from overseas markets [5] - LG Household & Health Care acquired 75% of Vivawave for 42.5 billion KRW in October 2023, aiming to leverage hince's presence in Japan to expand into the mid-to-high-end cosmetics market [5] - LG Household & Health Care has faced performance pressures, with a 6.1% year-on-year decline in sales for the first three quarters of 2025, and has appointed a new CEO to accelerate reforms and enhance product development [6]

Core Viewpoint - The major shareholder of Hyaluronic Acid giant, Huaxi Biological, has reduced its stake, indicating potential shifts in shareholder dynamics and company performance concerns [1][3]. Shareholder Actions - Guoshou Chengda reduced its holdings by 4.85 million shares, representing 1.01% of the total shares, leaving it with 24.08 million shares, or approximately 5.00% of the total share capital [1][3]. - The reduction was part of a planned divestment, with a total of up to 9.63 million shares (2.00% of total shares) expected to be sold between November 26, 2025, and February 23, 2026 [3]. Company Performance - Huaxi Biological has faced declining profits since 2023, with revenue and net profit dropping by 4.45% and 38.97% respectively in 2023 [5]. - The functional skincare segment saw a revenue decrease of 18.45%, contributing to 61.84% of the main business income [5]. - In 2024, the company rebranded its personal health consumer products line to "Skin Science Innovation Transformation," but still reported a revenue decline of 11.61% to 5.371 billion CNY and a net profit drop of 70.59% to 174 million CNY [5]. Market Position - The company's stock price has seen significant declines, with a market value dropping from a peak of over 100 billion CNY to 21.892 billion CNY as of January 9, 2026 [6]. - The stock price has decreased by 12.71%, 50.48%, 23.34%, and 14.24% from 2022 to 2025 [6].

Group 1 - The core point of the news is that Shanghai Jiakai Biological Co., Ltd. has responded to the first round of inquiry from the Beijing Stock Exchange regarding compliance issues related to equity changes, control stability, product quality risks, and the sustainability of performance growth [2][4] Group 2 - Jiakai Biological was established in 2015 and focuses on the research, production, and sales of cosmetic functional raw materials, primarily used in skincare, masks, and hair care products [4] - The company plans to raise 310 million yuan through its IPO, which will be fully allocated to a project for annual production of 50 tons of functional plant extracts [4] - The company has seen significant valuation growth, from 3 billion yuan in 2020 to 24.7 billion yuan in 2025, reflecting an increase of over 7 times in five years [5] Group 3 - Revenue figures for Jiakai Biological from 2023 to the first three quarters of 2025 are 218 million yuan, 242 million yuan, and 195 million yuan, with year-on-year changes of 19.1%, 11.46%, and 7.91% respectively [5] - Net profit for the same period is 48 million yuan, 57 million yuan, and 47 million yuan, with year-on-year changes of -12.82%, 19.83%, and 16.91% respectively [5]

Core Viewpoint - Huaxi Biological (688363.SH) announced a share reduction by its major shareholder Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) between November 26, 2025, and January 7, 2026 [1] Summary by Category Share Reduction Details - The reduction will be executed through centralized bidding and block trading, with 2,844,591 shares (0.59%) reduced via centralized bidding and 2,008,000 shares (0.42%) via block trading [1] - The total reduction amounts to 4,852,591 shares, representing 1.01% of the company's total share capital [1] Post-Reduction Shareholding - After the reduction, Guoshou Chengda will hold 24,083,913 shares of Huaxi Biological, which constitutes approximately 5.00% of the total share capital [1]

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining global attention in the health industry for its potential anti-aging, DNA repair, and metabolic regulation benefits, with significant regulatory advancements expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2][19]. Regulatory Environment - The global regulatory landscape for NMN is shifting from strict restrictions to cautious openness, with significant milestones achieved in countries like Japan, Canada, the US, and Australia [17][18]. - In China, NMN has been approved as a new cosmetic ingredient and is on the path to becoming a recognized health food, with the National Market Supervision Administration listing it for health food approval in April 2025 [17][18]. Market Demand - The aging population in China is driving the "silver economy," with projections indicating that the elderly population will grow from 320 million to 390 million between 2025 and 2030, creating a substantial market for anti-aging products [19]. - The younger generation, particularly those born in the 1990s, is increasingly aware of anti-aging needs, further boosting market demand for NMN products [19]. Technological Advancements - Innovations in synthesis, quality testing, and delivery methods are driving the NMN industry forward, with full enzyme methods significantly enhancing production efficiency and reducing costs [21][22]. - The transition from chemical synthesis to full enzyme methods is leading to higher purity and environmental sustainability in NMN production [10][12]. Application Areas - NMN is primarily used in health supplements and cosmetics, with the health supplement market accounting for nearly 90% of its applications, including anti-aging and immune support products [24][28]. - Future applications are expected to expand into pet nutrition, medical health, and agricultural technology, opening new growth avenues for the industry [24][28]. Market Size and Growth - The NMN market in China is projected to exceed 3 billion yuan by 2025, driven by increasing regulatory clarity and expanding applications in various sectors [28][32]. - The market has been growing steadily since 2020, with significant penetration into health supplements and cosmetics [28][32]. Sales Channels - NMN products are primarily sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60% to 70% of market share [35][34]. - Brand private channels are also showing strong performance, capturing about 30% of the market share [35]. Certification and Standards - The "blue hat" certification for health foods in China represents the highest standard for NMN products, indicating safety and compliance [37]. - Achieving this certification could significantly reshape the market landscape for NMN products in China [37]. Future Prospects - The NMN industry is poised for growth, with regulatory breakthroughs expected to enhance market opportunities, particularly in the cosmetics sector [51]. - The potential for NMN in pet nutrition, medical health, and agricultural technology is also being explored, indicating a broadening of its application scope [53][56][58].

Core Viewpoint - Huaxi Bio announced a shareholding change involving its major shareholder Guoshou Chengda, which will not trigger a mandatory takeover bid and will not alter the control of the company [2] Group 1: Shareholding Change - Guoshou Chengda plans to reduce its shareholding as per the announcement made on November 5, 2025, regarding the share reduction plan [2] - After the shareholding change, Guoshou Chengda will hold 24,083,913 shares, representing approximately 5.00% of the total share capital of Huaxi Bio [2] - Guoshou Chengda does not have any concerted action parties, ensuring that the control structure of the company remains unchanged [2]

Group 1 - The core point of the news is that the controlling shareholder and several executive directors of Mao Geping Cosmetics plan to collectively reduce their holdings by up to 17.2 million H shares, accounting for no more than 3.51% of the company's total issued shares, due to personal financial needs [1][2] - The planned reduction is expected to raise approximately 1.4 billion HKD based on the closing price of 82 HKD per share on the announcement date [1] - Despite the reduction, the company emphasizes that it will not lead to a change in control or significantly impact governance and ongoing operations [1][2] Group 2 - The beauty industry is experiencing frequent reduction plans, with Mao Geping's announcement occurring just after its first anniversary of listing, amidst a backdrop of declining valuations in the domestic beauty market [2][3] - Mao Geping's stock price peaked at 130.6 HKD per share, but has since fallen by about 33%, resulting in a market cap loss of nearly 20 billion HKD [2] - The company reported a revenue of 2.588 billion CNY for the first half of 2025, a year-on-year increase of 31.3%, and a net profit of 670 million CNY, up 36.1%, although revenue growth has begun to slow [2][7] Group 3 - The domestic beauty industry is shifting from an incremental market to a stock market, with a high entry and elimination rate among brands [6] - High-end beauty products are becoming a significant focus, with sales growth for products priced over 1,000 CNY increasing by 531.6% during the 2025 Double Eleven shopping festival [6] - Mao Geping maintains a high gross margin of over 80%, but faces scrutiny over its low R&D investment, which was only 15.257 million CNY in the first half of 2025 [7] Group 4 - The company is characterized by a high degree of founder centralization, with Mao Geping's personal brand being integral to the company's identity and operations [4][5] - The company is constructing a research and development center in Hangzhou, expected to be completed by the end of 2026, to enhance product design and development capabilities [7] - Balancing family wealth management with corporate growth while addressing R&D shortcomings and reducing dependence on the founder will be crucial for the company's sustained presence in the high-end beauty market [7]

华熙生物科技股份有限公司 简式权益变动报告书 上市公司名称：华熙生物科技股份有限公司 股票上市地点：上海证券交易所 股票代码：688363 信息披露义务人名称：国寿成达（上海）健康产业股权投资中心（有限合伙） 通讯地址：北京市朝阳区东三环中路 5 号财富金融中心 67 层 注册地址：中国（上海）自由贸易试验区银城路 88 号 39 楼 06 单元 邮政编码：100020 股份变动性质：股份减少及持股比例减少至 5% 签署日期：2026 年 1 月 8 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公司信 息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"《准则 15 号》"） 及相关的法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》、《收购办法》、《准则 15 号》的规定，本报告书已全面 披露了信息披露义务人在华熙生物科技股份有限公司中拥有 ...

证券代码：688363 证券简称：华熙生物 公告编号：2026-001 华熙生物科技股份有限公司 关于持股 5%以上股东权益变动触及 5%刻度 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 因实施本次减持计划，国寿成达权益变动触及 1%刻度的提示性公告请见公 司于 2025 年 11 月 28 日在上海证券交易所网站（www.sse.com.cn）披露的《华 熙生物科技股份有限公司关于持股 5%以上股东权益变动触及 1%刻度的提示性 公告》（公告编号：2025-045）。 本次权益变动为公司大股东国寿成达（上海）健康产业股权投资中心（有 限合伙）（以下简称"国寿成达"）根据公司于 2025 年 11 月 5 日在上 海证券交易所网站（www.sse.com.cn）披露的《华熙生物科技股份有限 公司股东减持股份计划公告》（公告编号：2025-043）（以下简称：本 次减持计划）作出的减持，不触及要约收购。 本次权益变动后国寿成达拥有权益的股份数量为 24,083,913 股，占公司 总股本的比 ...

Group 1 - The main subject of the equity change is Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership), with major partners including China Life Insurance Co., Ltd. (74.94%), China Life Insurance (Group) Company (16.65%), and China Life Property & Casualty Insurance Co., Ltd. (8.33%) [1] - The equity change involved a reduction from 28,936,504 shares (6.01% of total equity) to 24,083,913 shares (5.00% of total equity), resulting in a decrease of 4,852,591 shares, which is a reduction ratio of 1.0074% [1] - The reduction occurred between November 26, 2025, and January 7, 2026, through concentrated bidding for 2,844,591 shares (0.5906%) and block trading for 2,008,000 shares (0.4169%), with the shares being unrestricted circulating A-shares [1] Group 2 - The disclosed reduction plan has not been fully implemented, with a plan to reduce no more than 2.00% of the total equity by February 23, 2026, and there is a possibility of further reductions in the next 12 months [1]